$ News

Regeneron to deploy Telesis Bio’s Gibson SOLA at R&D facilities

Telesis Bio Announces Licensing Agreement with Regeneron to Adopt Gibson SOLA™ Platform for Rapid On-Site DNA and Gene Synthesis

Telesis Bio Secures up to $21 Million to Accelerate Adoption of Groundbreaking Gibson SOLA Technology for Rapid DNA and mRNA Synthesis

Telesis Bio: Q3 Earnings Snapshot

Telesis Bio Announces Departure of Chief Legal Officer

Telesis Bio partners with Danaher company Beckman Coulter

Telesis Bio and Beckman Coulter Life Sciences Collaborate to Revolutionize DNA and mRNA Synthesis

Telesis Bio Plans to Delist its Securities from The Nasdaq Stock Market

Telesis Bio Plans to Delist its Securities from The Nasdaq Stock Market

Telesis Bio to delist shares from Nasdaq

Telesis Bio to delist its securities from Nasdaq

Telesis Bio Board Shake-Up: New Chair, Committee Restructuring

Telesis Bio GAAP EPS of -$7.62, revenue of $1.6M

Telesis Bio: Q2 Earnings Snapshot

Telesis Bio Reports Second Quarter and First Half 2024 Financial Results

TBIO Stock Earnings: Telesis Bio Misses EPS, Misses Revenue for Q2 2024

Telesis Bio (TBIO) Gets a Buy from TD Cowen

Telesis Bio’s New Financing and Governance Shake-Up